Cargando…

Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs

The sustained cell proliferation resulting from dysregulation of the cell cycle and activation of cyclin-dependent kinases (CDKs) is a hallmark of cancer. The inhibition of CDKs is a highly promising and attractive strategy for the development of anticancer drugs. In particular, third-generation CDK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Kai, Wang, Xiao, Dong, Haojie, Min, Wenjian, Hao, Haiping, Yang, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838032/ https://www.ncbi.nlm.nih.gov/pubmed/33532179 http://dx.doi.org/10.1016/j.apsb.2020.05.001

Ejemplares similares

CDK7 inhibitors as anticancer drugs
por: Sava, Georgina P., et al.
Publicado: (2020)

Targeting CDK4/6 for Anticancer Therapy
por: Qi, Jiating, et al.
Publicado: (2022)

Inhibiting CDK6 Activity by Quercetin Is an Attractive Strategy for Cancer Therapy
por: Yousuf, Mohd, et al.
Publicado: (2020)

Metformin as a senostatic drug enhances the anticancer efficacy of CDK4/6 inhibitor in head and neck squamous cell carcinoma
por: Hu, Qinchao, et al.
Publicado: (2020)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
por: Pack, Lindsey R., et al.
Publicado: (2021)

The transcriptome of CDK4/6 inhibition
por: Knudsen, Erik S., et al.
Publicado: (2017)

Unexpected Outcomes of CDK4/6 Inhibition
por: Choi, Yoon Jong, et al.
Publicado: (2013)

Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition
por: Wood, Daniel J., et al.
Publicado: (2019)

Pharmacological Modulation of SAMHD1 Activity by CDK4/6 Inhibitors Improves Anticancer Therapy
por: Castellví, Marc, et al.
Publicado: (2020)

CDK4/6 inhibition in luminal breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2016)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis
por: Hellvard, Annelie, et al.
Publicado: (2016)

Recent advances of highly selective CDK4/6 inhibitors in breast cancer
por: Xu, Hanxiao, et al.
Publicado: (2017)

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2019)

Combining a CDK4/6 Inhibitor With Pemetrexed Inhibits Cell Proliferation and Metastasis in Human Lung Adenocarcinoma
por: Ke, Yuan, et al.
Publicado: (2022)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

CDK4/6 inhibition: the late harvest cycle begins
por: Goel, Shom, et al.
Publicado: (2016)

CDK4/6 inhibition triggers anti-tumor immunity
por: Goel, Shom, et al.
Publicado: (2017)

CDK6 Inhibition: A Novel Approach in AML Management
por: Uras, Iris Z., et al.
Publicado: (2020)

Inhibition of Mitochondrial Antioxidant Defense and CDK4/6 in Mesothelioma
por: Kratzke, Marian, et al.
Publicado: (2023)

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2019)

CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
por: Yang, Yilan, et al.
Publicado: (2020)

CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)
por: Huang, Jinyao, et al.
Publicado: (2022)

Selected Office Based Anticancer Treatment Strategies
por: Stoff, Jesse A.
Publicado: (2019)

MicroRNA-129 Inhibits Glioma Cell Growth by Targeting CDK4, CDK6, and MDM2
por: Moradimotlagh, Atieh, et al.
Publicado: (2019)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
por: Zhu, Lin, et al.
Publicado: (2022)

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
por: Kang, Jian, et al.
Publicado: (2014)

CDK4/6 inhibition is more active against the glioblastoma proneural subtype
por: Li, Ming, et al.
Publicado: (2017)

CDK9 inhibition strategy defines distinct sets of target genes
por: Garriga, Judit, et al.
Publicado: (2014)

Cyclin E1-CDK 2, a potential anticancer target
por: Fang, Dongdong, et al.
Publicado: (2016)

Cdk8 attenuates lipogenesis by inhibiting SREBP-dependent transcription in Drosophila
por: Li, Xiao, et al.
Publicado: (2022)

Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells
por: Pandey, Somnath, et al.
Publicado: (2022)

A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas
por: Hadjadj, Djihad, et al.
Publicado: (2017)

The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma
por: Suppramote, Orawan, et al.
Publicado: (2022)

CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy
por: Nardone, Valerio, et al.
Publicado: (2021)

Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs
por: Vagapova, Elmira, et al.
Publicado: (2021)

Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma
por: Rihani, Ali, et al.
Publicado: (2015)

p18 inhibits reprogramming through inactivation of Cdk4/6
por: Zhu, Shaohua, et al.
Publicado: (2016)

CDK4/6 inhibition in cancer: the cell cycle splicing connection
por: Sheppard, Karen E., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5i5ujfjp1h1rl5bi2rrnn53131